CureMetrix has announced a partnership with Therapixel to integrate CureMetrix’s cmAngio and Therapixel’s MammoScreen technologies. The partnership aims to expand access to both AI-based mammography solutions for radiologists and healthcare providers.
cmAngio is FDA-cleared AI-based software that reads mammograms and detects and localizes breast arterial calcifications. The software analyzes screening mammograms to identify and mark these findings, allowing radiologists to identify women who have breast arterial calcifications and refer them for additional evaluation as appropriate. cmAngio is live at hundreds of sites across the United States and has been offered to almost one million women.
MammoScreen is a breast cancer detection AI that assists radiologists in reading mammograms. The software incorporates 2D, 3D, and prior screenings into its evaluation and generates a report with a scoring system. MammoScreen provides image quality analysis, patient health history alerts, and can generate a draft report. Clinical studies have shown the technology reduces reader fatigue and inter-reader variability.
“This partnership aligns two innovators committed to transforming women’s health,” said Kevin Harris, President of CureMetrix. “By integrating cmAngio with Therapixel’s MammoScreen, we are broadening our reach, unifying installation for customers, and helping radiologists deliver deeper, data-driven insights that can improve outcomes for patients.”
“We’re proud to partner with CureMetrix to bring even more clinical value to our customers,” said Matthieu Leclerc-Chalvet, CEO of Therapixel. “Two best-in-class products, MammoScreen and cmAngio, now combine to empower radiologists to work smarter, improve quality and consistency, and make more informed decisions in breast imaging.”
The integration creates a combined approach to screening for both breast cancer and breast arterial calcifications through mammograms.
